Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Related Posts
Snap shares soar on better-than-expected profit and revenue
Snap reported better-than-expected fourth-quarter results on Tuesday but issued earnings guidance that trailed estimates.
Court rejects Boeing plea deal tied to 737 Max crashes
A federal judge rejected Boeing’s deal with the Justice Department to plead guilty to a criminal fraud charge tied to fatal crashes of 737 Max […]
Investors are pumping money into the Trump trade. Here’s how it did last time
Traders hope Donald Trump’s return to the White House will favor stocks tied to the President-elect’s policies. Some observers urge caution.